Innovative diagnostics deliver reliable and actionable information, resulting in better clinical and economic health care outcomes globally.
Alere is committed to delivering high-quality products and services that patients and providers can rely on for consistently accurate and actionable information. We deploy unique innovative technologies that not only transform diagnostic products, but also expand into new platforms and solutions with proven health and economic outcomes.
Faster than other molecular methods and more accurate than conventional rapid tests, the Alere™ i Strep A allows you to test and treat in one visit. 1,2
Highly accurate, molecular results in less than 15 minutes. Rapid diagnosis of influenza can lead to reduced hospital stays, secondary complications and cost of hospital care.1,2
Run the Alere™ i Influenza A & B test in any setting, from the laboratory to the physician’s office.
A multi-assay instrument that uses isothermal nucleic acid amplification technology to yield high sensitivity and specificity.
Learn more about the isothermal nucleic acid amplification technology behind the Alere™ i Influenza A&B rapid test.
Alere Determine™ HIV-1/2 Ag/Ab Combo is a 4th generation test that has the ability to detect HIV earlier than 2nd and 3rd generation antibody-only tests.2 It can detect infection three weeks after it occurs as opposed to other tests that can only detect it after three months. This enables health care providers to diagnose HIV infection earlier allowing individuals to seek medical care sooner.
Breaking the HIV Infection Cycle
Identifying HIV infection early, during the most infectious stage, offers significant benefits, particularly in high-risk populations such as men who have sex with men and injecting drug users.
Get the Facts
Rapid detection also helps to get patients into effective care and treatment earlier.
Individuals who are unaware of their infection are 3.5 times more likely to transmit the virus to someone else.1
By detecting HIV earlier, further transmission can be prevented during this highly infectious stage.
Learn how to conduct a fingerstick whole blood test procedure using the Alere Determine™ HIV-1/2 Ag/Ab Combo Assay.
Learn how to conduct a serum and plasma test procedure using the Alere Determine™ HIV-1/2 Ag/Ab Combo Assay.
Learn how to conduct a venipuncture whole blood test procedure using the Alere Determine™ HIV-1/2 Ag/Ab Combo Assay.
The new Alere Shiga Toxin Quik Chek™ assay is the only rapid test able to detect shiga toxin-producing E. Coli (STEC) toxins directly from fecal samples. The assay simultaneously detects and differentiates Stx1 and Stx2 toxins from STEC.
Easy to Use
The Alere C. Diff Quik Chek Complete™ test is the only rapid cassette assay that simultaneously detects both glutamate dehydrogenase (GDH) antigen and toxins A & B of C. difficile in fecal specimens. The test detects C. difficile antigen, GDH, as a screen for the presence of C. difficile and confirms the presence of toxigenic C. difficile by detecting toxins A and B in fecal specimens from persons suspected of having C. difficile disease.
The Alere Afinion™ AS100 Analyzer is designed to enable simple and fast on-the-spot testing, regardless of the sample type, which may be whole blood or urine. Deliver accurate results during consultation for improved patient management.
Alere™ Afinion™ HbA1c is the fastest point-of-care test in the market, providing results in just three minutes. Now you can obtain reliable results quickly and conveniently.
Alere™ Afinion™ ACR Cartridges provides a simple, fast and reliable point of care test for determination of albumin, creatinine and albumin/creatinine ratio (ACR) in human urine, which can indicate microalbuminuria.
1. Williams, KM, Jackson MA, Hamilton M. (2002) Rapid Diagnostic Testing for URIs in Children: Impact on Physician Decision Making and Cost. Infect. Med. 19(3): 109-111.
2. Bonner, A.B. et al. (2003) Impact of the Rapid Diagnosis of Influenza on Physician Decision-Making and Patient Management in the Pediatric Emergency Department: Results of a Randomized, Prospective, Controlled Trial. Pediatrics. Vol. 112 No. 2.